Compare Bath & Body Works Inc (BBWI) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Illumina, Inc. — how do they compare? Bath & Body Works Inc trades at $18.99 (market cap $3.89B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Illumina, Inc. is far larger — about 7.4× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.14% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| BBWI | ILMN | |
|---|---|---|
Market Cap | $3.89B | $28.96B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $205.10 |
52-Week Low | $14.85 | $91.00 |
Enterprise Value | $7.79B | $30.32B |
Dividend Yield | 4.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $20.36, up 1.09% daily, with a bearish technical signal but strong fundamentals including a low P/E of 5.78 and net income margin of 10.03%. Recent earnings show mixed beats, while cash flow trends improved in 2026 forecasts. The company expands globally via Ulta Beauty partnerships and Brazil entry, supporting growth narratives amid revenue declines from $7.9B in 2022 to $7.3B in 2025.
Outlook balances deep value with execution risks; analyst consensus price target of $22.11 implies upside, but high debt and revenue pressures require monitoring turnaround initiatives. Opportunities lie in margin strength and expansion, while risks include competitive retail headwinds and liability management.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
